Alzheimer's Disease Education and Referral Center

Pomegranate Juice and Memory

Pomegranate Juice and Memory

Overall Status: 
Recruiting
Brief Description: 

This study will examine whether drinking pomegranate juice daily for 1 year will benefit cognitive abilities in middle-aged and older adults without dementia. Researchers predict that participants who drink pomegranate juice will show better cognitive performance than those who drink a placebo.

Patient Qualifications: 
Min AgeMax AgeGenderHealthy Volunteers
50 Years
75 Years
Both
Accepts Healthy Volunteers
Inclusion Criteria: 
    • Normal cognition or mild cognitive impairment
    • Adequate seeing and hearing ability to allow neuropsychological testing
    • Screening laboratory tests and EKG without significant abnormalities that might interfere with the study; if tests show abnormalities, subject must obtain written clearance from primary care physician
Exclusion Criteria: 
    • Diagnosis of probable Alzheimer's disease or any other dementia
    • Evidence of other neurological or physical illness that can produce cognitive deterioration
    • History of stroke, transient ischemic attack, carotid bruits, or lacunes seen on MRI scan
    • Contraindication to MRI, including claustrophobia, metal in body, surgery within past 60 days, certain implants, or previous abnormal MRI results
    • Evidence of Parkinson's disease
    • History of myocardial infarction within the past year or unstable cardiac disease
    • Uncontrolled hypertension (systolic blood pressure > 170 mm Hg or diastolic blood pressure > 100 mm Hg)
    • History of significant liver disease, clinically significant pulmonary disease, or diabetes
    • Current diagnosis of any major psychiatric disorder
    • Current diagnosis or history of alcoholism or substance addiction
    • Pregnancy
    • Regular use of any medication that may affect cognitive functioning, including: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, antipsychotics, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anticonvulsants, or warfarin
    • Occasional use of anxiety or sleeping medications known to cause cognitive dulling will be allowed but discouraged: chloral hydrate; non-benzodiazepine hypnotics such as Ambien (zolpidem) or Lunesta (eszopiclone); benzodiazepines such as Ativan (lorazepam), Xanax (alprazolam), Klonopin (clonazepam), and Restoril (temazepam)
    • Other prohibited medications: amitriptyline, amiodarone, desipramine, fenofibrate, flecainide, fluconazole, fluoxetine, fluvastatin, fluvoxamine, isoniazid, lovastatin, ondansetron, phenylbutazone, probenecid, sertraline, sulfamethoxazole, sulfaphenazole, teniposide, voriconazole, and zafirlukast; supplements such as ginkgo biloba or anything containing pomegranate or pomegranate juice
Detailed Description: 

Participants will be randomly assigned to one of two groups: a treatment group that drinks 8 oz. (1 cup) of pomegranate juice daily for 1 year or a control group that drinks a placebo. All participants will undergo an initial clinical assessment, a magnetic resonance imaging scan of the brain, and a blood test to determine genetic risk and rule out other neurodegenerative disorders linked to memory complaints. Cognitive performance will be measured at 1, 6, and 12 months. The investigators believe that changes in cognition will vary according to a genetic risk for Alzheimer's.

Locations: 
Map Marker CityStateZip CodeStatusPrimary Contact

Geolocation is 34.070264, -118.4440562

Site
Los Angeles
California
90095
Recruiting
Name: Anya Rosensteel
Phone: 310-825-0545
Email: arosensteel@mednet.ucla.edu
Lead Sponsor: 
Agency
University of California, Los Angeles
Collaborator Sponsor: 
Agency
POM Wonderful LLC
Facility Investigators: 
NameRoleAffiliation
Gary Small, MD
Principal Investigator
UCLA Longevity Center
Study Contact: 
NamePhoneEmail
Anya Rosensteel
310-825-0545
Natacha Donoghue
310-206-7392
Locations
 
 
ClinicalTrials.gov ID 
NCT02093130 (follow link to view full record on ct.gov in new window)
Official Title: 
Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging
Study Start Date: 
January 2014
Study End Date: 
March 2016
Enrollment: 
212